Judith Balmaña
Advertisement
Articles by Judith Balmaña
Advertisement
Latest Updated Articles
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)Published: April 22nd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Breakthrough Therapy Designation to ICT01 in Frontline AML
2
Report Finds Seventy Percent 5-Year Survival Rate for All Cancers Combined
3
Gemogenovatucel-T Exhibits Survival Benefit in Epithelial Ovarian Cancer
4
FDA Accepts sBLA for Ropeginterferon in Essential Thrombocytopenia
5